MX2013013436A - Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. - Google Patents
Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.Info
- Publication number
- MX2013013436A MX2013013436A MX2013013436A MX2013013436A MX2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A MX 2013013436 A MX2013013436 A MX 2013013436A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- indole derivatives
- substituted indole
- immunological disorders
- substituted
- Prior art date
Links
- 229940054051 antipsychotic indole derivative Drugs 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title abstract 2
- 208000026278 immune system disease Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/499—Spiro-condensed pyrazines or piperazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486808P | 2011-05-17 | 2011-05-17 | |
| PCT/IB2012/052473 WO2012156936A1 (en) | 2011-05-17 | 2012-05-16 | Substituted indole derivatives for the treatment of immunological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013013436A true MX2013013436A (es) | 2013-12-06 |
Family
ID=46210333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013436A MX2013013436A (es) | 2011-05-17 | 2012-05-16 | Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8703782B2 (enExample) |
| EP (1) | EP2709998B1 (enExample) |
| JP (1) | JP6043344B2 (enExample) |
| KR (1) | KR20140023354A (enExample) |
| CN (1) | CN103534250B (enExample) |
| AR (1) | AR088414A1 (enExample) |
| AU (1) | AU2012257345B2 (enExample) |
| BR (1) | BR112013029416A2 (enExample) |
| CA (1) | CA2835169C (enExample) |
| EA (1) | EA023238B1 (enExample) |
| ES (1) | ES2565200T3 (enExample) |
| MX (1) | MX2013013436A (enExample) |
| TW (1) | TW201249858A (enExample) |
| UY (1) | UY34072A (enExample) |
| WO (1) | WO2012156936A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| MX2015005737A (es) * | 2012-11-07 | 2015-09-16 | Novartis Ag | Derivados de indol sustituido. |
| MX378263B (es) * | 2013-08-14 | 2025-03-10 | Novartis Ag | Terapia de combinación para el tratamiento del cáncer. |
| JP6998657B2 (ja) | 2013-09-18 | 2022-02-04 | エピアクシス セラピューティクス プロプライエタリー リミテッド | 幹細胞調節ｉｉ |
| EP3185858A4 (en) | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| WO2025091442A1 (zh) * | 2023-11-03 | 2025-05-08 | 北京凯因科技股份有限公司 | 一种神经氨酸酶抑制剂及在流感病毒中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925860A (en) | 1987-08-05 | 1990-05-15 | E. I. Du Pont De Nemours And Company | Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester |
| DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
| US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| NZ518038A (en) | 1999-10-12 | 2004-02-27 | F | Substituted pyrroles as antiproliferative agents for the treatment of cancer |
| PE20020544A1 (es) * | 2000-11-07 | 2002-07-30 | Novartis Ag | Derivados de indolilmaleimida |
| CA2470423C (en) | 2001-12-21 | 2011-03-15 | Guilford Pharmaceuticals, Inc. | Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol |
| CA2470500C (en) | 2001-12-28 | 2012-05-15 | Guilford Pharmaceuticals, Inc. | Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| AR039209A1 (es) | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
| EP1492544A4 (en) | 2002-04-08 | 2005-10-12 | Guilford Pharm Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING PROPOFOL-BASED WATER-SOLUBLE PRODRUGS AND METHODS OF ADMINISTRATION THEREOF |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2003223104A1 (en) | 2003-03-19 | 2004-10-11 | Suven Life Sciences Limited | A process for the preparation of indolymaleimides |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2007008514A2 (en) | 2005-07-07 | 2007-01-18 | Georgetown University | Inhibitors of glycogen synthase kinase 3 |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| GB0605691D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| US8163902B2 (en) | 2006-11-21 | 2012-04-24 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| WO2011057204A2 (en) | 2009-11-06 | 2011-05-12 | The Johns Hopkins University | Lrrk2-mediated neuronal toxicity |
| CN101812097B (zh) | 2010-04-17 | 2012-04-25 | 中国海洋大学 | 吲哚咔唑和双吲哚马来酰亚胺生物碱及其制备方法和应用 |
| UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
-
2012
- 2012-05-14 UY UY34072A patent/UY34072A/es not_active Application Discontinuation
- 2012-05-15 US US13/471,512 patent/US8703782B2/en active Active
- 2012-05-16 EA EA201391710A patent/EA023238B1/ru not_active IP Right Cessation
- 2012-05-16 CN CN201280023473.2A patent/CN103534250B/zh active Active
- 2012-05-16 BR BR112013029416A patent/BR112013029416A2/pt not_active IP Right Cessation
- 2012-05-16 TW TW101117465A patent/TW201249858A/zh unknown
- 2012-05-16 KR KR20137030038A patent/KR20140023354A/ko not_active Withdrawn
- 2012-05-16 MX MX2013013436A patent/MX2013013436A/es not_active Application Discontinuation
- 2012-05-16 WO PCT/IB2012/052473 patent/WO2012156936A1/en not_active Ceased
- 2012-05-16 CA CA2835169A patent/CA2835169C/en active Active
- 2012-05-16 EP EP12726226.9A patent/EP2709998B1/en active Active
- 2012-05-16 ES ES12726226.9T patent/ES2565200T3/es active Active
- 2012-05-16 JP JP2014510933A patent/JP6043344B2/ja active Active
- 2012-05-16 AU AU2012257345A patent/AU2012257345B2/en active Active
- 2012-05-18 AR ARP120101769 patent/AR088414A1/es not_active Application Discontinuation
-
2014
- 2014-03-03 US US14/194,879 patent/US9029396B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EA201391710A1 (ru) | 2014-03-31 |
| US9029396B2 (en) | 2015-05-12 |
| BR112013029416A2 (pt) | 2017-01-31 |
| CA2835169A1 (en) | 2012-11-22 |
| US8703782B2 (en) | 2014-04-22 |
| ES2565200T3 (es) | 2016-04-01 |
| CA2835169C (en) | 2019-05-14 |
| UY34072A (es) | 2013-01-03 |
| TW201249858A (en) | 2012-12-16 |
| CN103534250B (zh) | 2016-05-11 |
| EP2709998B1 (en) | 2016-01-06 |
| CN103534250A (zh) | 2014-01-22 |
| US20130157980A1 (en) | 2013-06-20 |
| AU2012257345B2 (en) | 2016-03-24 |
| EP2709998A1 (en) | 2014-03-26 |
| JP2014518870A (ja) | 2014-08-07 |
| AR088414A1 (es) | 2014-06-11 |
| JP6043344B2 (ja) | 2016-12-14 |
| KR20140023354A (ko) | 2014-02-26 |
| EA023238B1 (ru) | 2016-05-31 |
| US20140179634A1 (en) | 2014-06-26 |
| WO2012156936A1 (en) | 2012-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501289A1 (en) | Novel benzimidazole derivatives as ep4 antagonists | |
| IN2015KN00262A (enExample) | ||
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| TN2016000127A1 (en) | Heteroaryl butanoic acid derivatives as lta4h inhibitors. | |
| TN2015000120A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| EA201500112A1 (ru) | 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств | |
| TN2016000107A1 (en) | Substituted phenylalanine derivatives | |
| MX2013013436A (es) | Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos. | |
| MX2014004210A (es) | Derivados de 2-oxo-piperidinilo. | |
| IN2015DN00950A (enExample) | ||
| PH12016501764A1 (en) | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators | |
| MX2016011900A (es) | Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2. | |
| WO2014122671A3 (en) | Solid oral compositions of saxagliptin | |
| MX364929B (es) | Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5-ht4. | |
| IN2015DN02660A (enExample) | ||
| MX2014004742A (es) | Nuevos agentes antibacterianos de fenicol. | |
| TN2013000243A1 (en) | Substituted 1-benzylcycloalkylcarboxlic acids and use thereof | |
| MX2015012393A (es) | Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |